MX2023004381A - Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores solidos. - Google Patents

Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores solidos.

Info

Publication number
MX2023004381A
MX2023004381A MX2023004381A MX2023004381A MX2023004381A MX 2023004381 A MX2023004381 A MX 2023004381A MX 2023004381 A MX2023004381 A MX 2023004381A MX 2023004381 A MX2023004381 A MX 2023004381A MX 2023004381 A MX2023004381 A MX 2023004381A
Authority
MX
Mexico
Prior art keywords
compositions
solid tumors
treating solid
naphthyridine derivatives
aluminium adjuvant
Prior art date
Application number
MX2023004381A
Other languages
English (en)
Inventor
Shailaja Kasibhatla
Andrew T Miller
Michael Cooke
Tom Yao - Hsiang Wu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2023004381A publication Critical patent/MX2023004381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención proporcionada en el presente documento incluye composiciones farmacéuticas que comprenden un agonista de TLR7 que tiene la estructura de Fórmula (A), partículas que contienen aluminio y uno o más excipientes farmacéuticamente aceptables. La invención proporciona además el uso de tales composiciones en el tratamiento de tumores sólidos ya sea solas o en combinación con una o más composiciones farmacéuticas adicionales.
MX2023004381A 2017-05-19 2019-11-15 Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores solidos. MX2023004381A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508474P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
MX2023004381A true MX2023004381A (es) 2023-05-04

Family

ID=62597814

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013720A MX2019013720A (es) 2017-05-19 2018-05-17 Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para uso en el tratamiento de tumores solidos.
MX2023004381A MX2023004381A (es) 2017-05-19 2019-11-15 Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores solidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019013720A MX2019013720A (es) 2017-05-19 2018-05-17 Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para uso en el tratamiento de tumores solidos.

Country Status (13)

Country Link
US (2) US11752162B2 (es)
EP (1) EP3624806A1 (es)
JP (2) JP2020520910A (es)
KR (1) KR20200007040A (es)
CN (2) CN116473981A (es)
AR (1) AR111760A1 (es)
AU (2) AU2018268420B2 (es)
BR (1) BR112019024260A2 (es)
CA (1) CA3062609A1 (es)
CL (1) CL2019003293A1 (es)
MX (2) MX2019013720A (es)
TW (1) TW201900166A (es)
WO (1) WO2018211453A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
KR101494056B1 (ko) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
WO2009111337A1 (en) 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
AU2010258677B2 (en) 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
DK2459216T3 (da) 2009-09-02 2013-12-09 Novartis Ag Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
ES2708989T3 (es) * 2010-03-31 2019-04-12 Stabilitech Biopharma Ltd Método de conservación de adyuvantes de alumbre y vacunas potenciadas con alumbre
EP2558069A1 (en) 2010-04-13 2013-02-20 Novartis AG Benzonapthyridine compositions and uses thereof
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2532359A1 (en) * 2011-06-10 2012-12-12 Affiris AG CETP fragments
EP2734551B1 (en) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
MX2014002363A (es) * 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP3770176A1 (en) 2013-05-02 2021-01-27 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
JP6502959B2 (ja) 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
BE1022875B1 (fr) 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3174538B1 (en) 2014-08-01 2019-11-06 3M Innovative Properties Company Methods and therapeutic combinations for treating tumors
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20190091306A1 (en) 2015-11-03 2019-03-28 Affiris Ag Method for vaccination against a self-antigen in a human patient

Also Published As

Publication number Publication date
CL2019003293A1 (es) 2020-03-13
US20210154214A1 (en) 2021-05-27
CN110636848A (zh) 2019-12-31
CA3062609A1 (en) 2018-11-22
MX2019013720A (es) 2020-01-30
AU2018268420A1 (en) 2019-11-21
RU2019141837A (ru) 2021-06-21
AU2018268420B2 (en) 2021-07-15
EP3624806A1 (en) 2020-03-25
CN116473981A (zh) 2023-07-25
US11752162B2 (en) 2023-09-12
KR20200007040A (ko) 2020-01-21
AR111760A1 (es) 2019-08-14
WO2018211453A1 (en) 2018-11-22
US20240009215A1 (en) 2024-01-11
AU2021203564A1 (en) 2021-07-01
TW201900166A (zh) 2019-01-01
BR112019024260A2 (pt) 2020-06-09
JP2020520910A (ja) 2020-07-16
AU2021203564B2 (en) 2023-01-05
RU2019141837A3 (es) 2021-09-10
JP2023093524A (ja) 2023-07-04

Similar Documents

Publication Publication Date Title
MX2023004381A (es) Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores solidos.
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
AU2019901991A0 (en) Compositions and methods based on synergy between plumbagin and xanthohumol for the prevention and treatment of cancer
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
UA82584U (ru) Способ лечения вестибулярной мигрени и коморбидного синдрома головокружения у женщин с вестибулярной дисфункцией в перименопаузальном периоде